Evidence map›Paper›PMID 34417351›Full record

ArticleThorax2022

CHK yourself, before you wreck yourself: targeting the DNA damage response in secondary pulmonary hypertension.

Andrew Bryant, Vinicio de Jesus Perez

Open access · greenAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Thorax, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Andrew BryantMedicine, University of Florida College of Medicine, Gainesville, Florida, USA.
Vinicio de Jesus PerezMedicine, Stanford University, Stanford, California, USA vdejesus@stanford.edu.
Stanford University · USUniversity of Florida · US

Funding

The Wnt7a/ROR2 axis in the pathogenesis of pulmonary arterial hypertensionR01HL134776 · NHLBI · STANFORD UNIVERSITY · PI DE JESUS PEREZ, VINICIO A · 2017 to 2025
$5.0M
Endothelial-pericyte interactions in the pathogenesis of pulmonary arterial hypertensionR01HL139664 · NHLBI · STANFORD UNIVERSITY · PI DE JESUS PEREZ, VINICIO A · 2018 to 2025
$4.7M
Role of ADAM17 in MDSC-Mediated Development of Pulmonary HypertensionR01HL142887 · NHLBI · UNIVERSITY OF FLORIDA · PI BRYANT, ANDREW JUSTIN · 2020 to 2024
$1.9M
Role of CXCR2-mediated cell trafficking in pulmonary vascular remodelingR01HL142776 · NHLBI · UNIVERSITY OF FLORIDA · PI BRYANT, ANDREW JUSTIN · 2019 to 2023
$1.9M
NHLBI NIH HHS R01 HL134776NHLBI NIH HHS R01 HL139664NHLBI NIH HHS R01 HL142776NHLBI NIH HHS R01 HL142887
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hypertension, PulmonaryDNA DamageHumansidiopathic pulmonary fibrosisprimary pulmonary hypertension

Identifiers

PMID34417351
PMCPMC10015978
OpenAlexW3195841996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.